Cannabis Science, Inc. (OTCBB: CBIS), a pioneering U.S. biotech
company developing pharmaceutical cannabis (marijuana) products, is
pleased to provide insight on the upcoming release of its’ new
over-the-counter skin and nutraceutical product line to be branded
“Phytiva” through its newest venture Phytiva Pharmaceuticals Inc.
The Company is working as fast as it can to make its cannabis-based
formulations that target critical ailments more widely available
through multiple regulatory body guidelines. This approach will
allow the Company to release its formulations to multiple markets
reaching the maximum amount of people in the shortest time frame
across the nation and internationally. To support this cause
Cannabis Science has been working with numerous patients who have
been documenting their self-medicating treatment process using the
cannabis-extracts.
The Company continues to receive a large number of inquiries
about current and new product releases and operational updates on
its projects in the works. The Company is in the process of
updating its website to provide up-to-date timeline information on
its projects, product lines, events, conferences and other
important corporate and operational information for the public as
released for the public.
FDA Initiatives
Cannabis Science is working very close with its previously
announced FDA clinical trials consultants to guide the Company
through the formal FDA new product release regulatory guidelines.
The main steps required to be completed are as follows:
1. Pre-IND meeting with the FDA
*** The Company is currently in this stage and is working close
with its’ FDA advisory group towards requesting a pre-IND meeting
date. The Company has identified its initial target indication as
skin cancer and will present this case to the FDA at the pre-IND
meeting.
2. Application filing for IND – Number
Once the Company has presented its case at the pre IND meeting
with the FDA and makes any recommended adjustments to its case
study, it will then submit its formal application to the FDA for
the IND number application.
3. IND – Number assignment
FDA will assign an IND number for the case study once the
Company has completed a successful application process. The IND
number assignment will give the Company the green light to begin
its clinical trials.
4. Begin clinical trials
Once the Company has successfully completed the application
process and receives its IND number from the FDA it can then begin
formal clinical trials to prove the product viable for general
market consumption or use.
5. Successful IND product release
Working within the FDA regulatory procedures is paramount for
Cannabis Science. Once it receives full approvals from the FDA on
each of its target indications, it will then release its products
for patients in need of the treatments for their critical ailments
nationwide.
Over-the-counter Nutraceutical Product
Lines
This market opportunity for the Company and the people who are
looking for Cannabis Science formulations is very large and spans
the nation and beyond. The Company has identified several target
products to release and is finalizing a few for immediate OTC
market release. Our supporters recognize that these products
will help finance the company as we move forward with the FDA
process
Cannabis Science is rapidly moving to commercialize Phytiva,
our new over-the-counter skin and nutraceutical product
line to be available through its newest venture Phytiva
Pharmaceuticals Inc. Cannabis Science formulations for these
new products are finalized and we are making decisions for mass
manufacturing and nationwide distribution. With several products on
the roster for the Phytiva product line, the Company has made
public a few: a lip balm to improve the dryness of lips and
promote healing, a sunscreen with dual purposes to block the
sun, promote sunburn healing and relief, and a dry skin lotion that
enhance skin care for those suffering with Eczema and Psoriasis,
a fourth product is a facial and body moisturizer that
contains compounds with anti-aging properties that promote healthy
skin and appearance.
As we develop the initial products for the Phytiva Product line,
Cannabis Science is working on laterally expansion as we negotiate
to acquire new and effective products and treatment processes.
State Regulated Medical Cannabis
Dispensaries
The Company target initiatives in states that have approved
medical marijuana programs is based on the successful results being
reported by patients self-medicating using Cannabis Science
approved formulations through state licensed manufacturers and
distributors. The Company is working to expand availability of our
formulations across the nation on a state-by-state basis as states
continue to approve medical cannabis treatments.
Currently, Cannabis Science has its cannabis-based high quality
extract formulations available in Pueblo and Denver Colorado
through licensing agreements. As well, The Company has signed a
licensing deal with Apothecary Genetics in California to provide
the same full circle operations required under State regulated
medical cannabis laws to provide California State licensed medical
cannabis patients its formulations.
The Company has been receiving outstanding feed back from the
current patients using its formulations for Skin Cancer as
documented on the www.cannabisscience.com website.
Cannabis Science President & CEO,
Dr. Robert Melamede Ph.D. and the Science
In order for one to understand the unique health benefits
provided by cannabis extracts, including their ability to kill
numerous cancer cell types, one must examine the role of the
endocannabinoids system in maintaining and promoting human health.
The endocannabinoid system formally evolved with the appearance of
vertebrates, with the development of receptors that specifically
bind to the lipid derived endocannabinoids. Surprisingly, the
endocannabinoid system is a global, multi-scaled, homeostatic
regulator of all body systems. Thus, the cardiovascular, digestive,
endocrine, immune, musculoskeletal, nervous, reproductive, and
tegumentary systems are all kept in dynamic balance by the
endocannabinoid system through its ability to regulate mass and
energy flow (the munchies). All cells can only survive by
extracting what they need from their environment in order to
maintain their internal organization. Cannabinoids, including those
derived from the plant (phytocannabinoids), those produced by our
bodies (endocannabinoids), and those synthesized by man
(synthetics) can very powerfully promote the death of cancer cells
by disrupting their internal organization while minimizing the
ability of the environment to support them. Thus, unlike
conventional pharmaceuticals and anticancer agents that typically
target a single pathway (the magic bullet approach), cannabinoids
impact many aspects of cellular and organismic biochemistry to kill
cancers. The chemical complexity of concentrated cannabis extracts
holistically decreases the probability that a cancer cell can
survive while at the same time promoting general health, as
evidenced by the anti-aging and health promoting properties that
arise from stimulating the endocannabinoids system.
Melamede, R. Harm reduction--the cannabis paradox. Harm Reduct J
2, 17 (2005).
Sarfaraz, S., Adhami, V. M., Syed, D. N., Afaq, F. &
Mukhtar, H. Cannabinoids for cancer treatment: progress and
promise. Cancer Res 68, 339-342 (2008).
Massi, P., Solinas, M., Cinquina, V. & Parolaro, D.
CANNABIDIOL AS POTENTIAL ANTICANCER DRUG. Br J Clin Pharmacol
(2012).
Hermanson, D. J. & Marnett, L. J. Cannabinoids,
endocannabinoids, and cancer. Cancer Metastasis Rev (2011).
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical
grade medical marijuana research and development. The second
formulations will address the needs of patients choosing to use
concentrated cannabis extracts to treat their ailments. Eventually,
all Americans will have access to a safe and effective FDA approved
medicine regardless of which state they live in. To maintain that
marijuana is a dangerous, addictive drug with no medical value is
scientifically absurd. Cannabis medicines, with no effective lethal
dose, are far safer than aspirin, acetaminophen, and most other OTC
drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid
science targeting critical illnesses, and adheres to scientific
methodologies to develop, produce and commercialize
phytocannabinoid-based pharmaceutical products. In sum, we are
dedicated to the creation of cannabis-based medicines, both with
and without psychoactive properties, to treat disease and the
symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
works such as "anticipate," "seek," intend," "believe," "plan,"
"estimate," "expect," "project," "plan," or similar phrases may be
deemed "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Some or all of
the events or results anticipated by these forward-looking
statements may not occur. Factors that could cause or contribute to
such differences include the future U.S. and global economies, the
impact of competition, and the Company's reliance on existing
regulations regarding the use and development of cannabis-based
drugs. Cannabis Science, Inc. does not undertake any duty nor does
it intend to update the results of these forward-looking
statements.